BOARD OF DIRECTORS
John T. Spitznagel
Mr. Spitznagel most recently served as Chairman and Chief Executive officer for Esprit Pharma, Inc. a specialty pharmaceutical company focusing on the sale and marketing of pharmaceutical therapies to the genito-urinary market. After co-founding the Company in mid-2005, John was able to oversee the Esprit's acquisition, marketing and growth strategies, which led to the sale of Esprit to Allergan, Inc. for $370 million in October 2007. Previously, Mr. Spitznagel was Chairman and Chief Executive Officer of ESP Pharma, a specialty pharmaceutical company focused on acquiring in-market and late stage drugs for the acute care market. Within three years of initiating operations, ESP was acquired by Protein Design Labs for approximately $514 million in March 2005. Prior to ESP, John was President and Chief Executive Officer of Roberts Pharmaceuticals which was engaged in the acquisition, development and marketing of specialty pharmaceuticals. He joined Roberts in 1996 and is credited with leading that company through a dramatic turnaround in profitability. John ultimately engineered the successful merger of Roberts with Shire Pharmaceuticals in 1999 for approximately $1.2 billion ( a nearly four-fold expansion of market value during his tenure). Prior to his work at Roberts, John served as President of the Reed and Carnrick division of Block Drug from 1990 - 1995, where he also was responsible for a successful turnaround and sale of the division. John began his career in 1964 at Warner-Lambert in sales and marketing and spent nearly ten years at Hoffmann-La Roche and ten years at American Home Products where he was Senior Vice President of Marketing and Sales for Wyeth.
Mr. Spitznagel is a director at Wynden Pharmaceuticals, IRX Therapeutics and Chairman at Barbeau Pharmaceuticals. He is a trustee for Rider University where he earned a Bachelor's degree in Liberal Arts. John also holds an M.B.A. from Fairleigh Dickinson University.
top
David S. Tierney, M.D.
David S. Tierney, MD, was the President, Chief Executive Officer and a Director of Valera Pharmaceuticals, Inc., until it was acquired by Indevus Pharmaceuticals, Inc., in April 2007. From January 2000 to August 2000, Dr. Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he had responsibility for all of Biovail's research and development and regulatory and clinical activities. From March 1997 to January 2000, Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, with responsibility for all research and development activities, and overall responsibility for drug development, medical affairs, worldwide regulatory affairs and chemical process development, as well as being part of the executive management team. From December 1989 to March 1997, Dr. Tierney was at Élan Corporation in a variety of management positions. During his time at Élan Dr Tierney was involved in the development of numerous successful NDAs. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland, and subsequently trained in internal medicine.
Dr Tierney serves as non-executive Chairman of Bioject Inc (BJCT: NASDAQ) and is a member of the board of directors of Catalyst Pharmaceutical Partners (CPRX: NASDAQ) and Nexmed, Inc (NEXM: NASDAQ).
top
Bob More
Frazier Healthcare and Technology Ventures
Mr. More joined Frazier Healthcare in 2008 as a General Partner and is a member of the firm’s biopharma and medical device investment teams. Prior to Frazier Healthcare, Mr. More was a Partner with Domain Associates, having joined the firm in 1996 as a Kauffman Fellow and becoming a Partner in 2000. From 1997-1998, Mr. More served as the Chief Operating Officer of Small Molecule Therapeutics, a Domain portfolio company subsequently purchased by Morphochem AG. And from 1992 to 1995, Mr. More was with Pharmacia Biotech in sales. Prior to joining Pharmacia, Mr. More held a research position at Somatogen, a company developing a recombinant blood substitute that was subsequently bought by Baxter. While attending business school, Mr. More worked with MedVest, an early-stage venture group in Washington, D.C.
Mr. More managed successful investments in and served on the boards of ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), Onux Medical (acquired by C.R. Bard), NovaCardia (acquired by Merck), Esprit Pharma (acquired by Allergan) and IntraLase (acquired by Advanced Medical Optics, Inc.).
Mr. More serves as an advisory board member for Montagu Newhall Associates, Okapi Ventures, The Medical Industry Group of the NVCA and The Sulpizio Family Cardiovascular Center. He is also a past founding board member of the Kauffman Fellows Program.
Mr. More received his MBA from the Darden School of Business Administration at the University of Virginia and a BA from Middlebury College.
top
Matthew S. Edgerton
Kelso & Company
Matthew S. Edgerton, joined Kelso in 2005 as an Associate. Prior to joining the firm, he was an Analyst in the Investment Banking Division of Deutsche Bank. Mr. Edgerton received a B.A. in Economics and History from Duke University.
top
Christopher L. Collins
Kelso & Company
Christopher L. Collins joined Kelso in 2001 and is currently a Vice President. Prior to joining the Firm, he was enrolled at the Stanford Graduate School of Business, and prior to that he was an analyst at Stonington Partners. Mr. Collins received a B.A. in English with honors from Duke University and an M.B.A. (Finance and Business Policy) from the Stanford Graduate School of Business. Mr. Collins is also a director of AVSC Holding Corp., IGPS Company LLC, Buckeye GP Holdings, L.P. and Renfro Corporation.
top
Frank J. Loverro
Kelso & Company
Frank J. Loverro joined Kelso in 1993 and is currently a Managing Director. Prior to joining Kelso, he worked in private equity investing at the Clipper Group. Mr. Loverro started his career in the High Yield Finance Group at CS First Boston, where he focused on debt and equity financing alternatives for leveraged companies. Mr. Loverro received a B.A. with distinction in Economics from the University of Virginia. Mr. Loverro is also a director of KRH Investments, LLC and Buckeye GP Holdings, L.P.
top
|
